Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer
Status:
Recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
In the past three years, as the key protein suggested to be involved in host cell entry of
SARS-CoV-2, studies of ACE2 aroused people's attention again. Tracking the expression of ACE2
in vivo is crucial to further understanding of COVID-19, dynamically monitoring the effect of
antiviral therapy and the development of related vaccines. It is also expected to further
conduct in-depth research on the physiological effects of ACE2 and RAAS, and the mechanism of
ACEI/ARB (32). With the development of both molecular imaging agents and related equipment,
several ACE2-targeting PET imaging agents have been investigated based on different
strategies while some of them were tested in clinical trials. The aim of this study was to
intercept key ACE2-binding sites from coronavirus RBD and test their potential as
ACE2-targeting PET agents.